Goddard A F, Logan R P H
Derby City Hospital, Derby, UK.
Br J Clin Pharmacol. 2003 Sep;56(3):273-83. doi: 10.1046/j.1365-2125.2003.01941.x.
Helicobacter pylori is the principal cause of peptic ulcer disease and an important risk factor for the development of gastric cancer. The efficacy of 1 week triple therapies, which often have eradication rates of>90%, is undermined by poor patient compliance and bacterial antimicrobial resistance. The development of new anti-H. pylori therapies presents enormous challenges to clinical pharmacologists, not only in the identification of novel targets, but also in ensuring adequate drug delivery to the unique gastric mucus niche of H. pylori. Animal models of H. pylori infection have been developed but their clinical validity has yet to be established. Vaccination, to prevent or treat infection, has been demonstrated in animal models, but human studies have not been so encouraging.
幽门螺杆菌是消化性溃疡疾病的主要病因，也是胃癌发生的重要危险因素。1周的三联疗法通常根除率>90%，但其疗效因患者依从性差和细菌耐药性而受到影响。开发新的抗幽门螺杆菌疗法给临床药理学家带来了巨大挑战，不仅要识别新的靶点，还要确保将药物充分输送到幽门螺杆菌独特的胃黏液微环境中。已经建立了幽门螺杆菌感染的动物模型，但其临床有效性尚未得到证实。在动物模型中已证明疫苗接种可预防或治疗感染，但人体研究的结果却不那么令人鼓舞。
